帕尼单抗联合mFOLFOX6方案对老年结直肠癌患者的临床疗效

Clinical Effects of Panitumumab and mFOLFOX6 Regiments in the Treatment of Senile Colorectal Cancer

目的探讨帕尼单抗联合改良的FOLFOX6（mFOLFOX6）化疗方案对老年结直肠癌患者的临床疗效及安全性。方法80例KRAS野生型老年结直肠癌患者随机分为试验组40例和对照组40例。试验组患者给予帕尼单抗联合mFOLFOX6化疗方案，具体治疗方法为mFOLFOX6：奥沙利铂85mg／m2，第1d给药；亚叶酸钙400mg／m2，第1d给药；5-氟尿嘧啶第1d静脉推注400mg／m2，之后以2400mg／m2的剂量持续静脉滴注46h。每两周为1个周期；帕尼单抗6mg／kg，每两周给药1次。对照组患者仅给予mFOLFOX6方案化疗，方法同试验组。两组均治疗6个周期后探讨其临床疗效及不良反应。结果试验组患者的总有效率为67．5％，对照组为45．0％，试验组总有效率明显高于对照组（P〈0．05）；两组患者化疗后均出现不同程度的不良反应，经比较其差异无统计学意义（P〉0．05）。结论帕尼单抗联合mFOLFOX6化疗方案治疗KRAS野生型老年结直肠癌临床疗效满意，不良反应可以耐受，值得临床工作者推广。

Objective To observe the clinical effects and security of the Panitumumab and mFOLFOX6 regimens in the treatment of senile colorectal cancer. Methods 80 K - Ras wild - type patients with senile colorectal cancer were randomly divided into the experiment group and the control group. The experiment group received Panitumumab （6mg/kg biweekly） and mFOLFOX6 （ L - OHP 85 mg/m2 , leucovorin 400 mg/m2, 5 - fiuorouracil 400 mg/m2 bolus and 5 - fluorou - racial 2400 mg/m2 46 h infusion, biweekly）. The control group accepted mFOLFOX6. After treatment the therapeutic effects and adverse reactions were compared. Results In the experiment group and the control group the total effective rate was 67.5% and 45% respectively. The clinical effectiveness in the experiment group was obviously higher than that in the control group （ P 〈 0.05 ）. There were some side effects in the two groups. There was no statistical differences （P 〉 0. 05）. Conclusion The Panitumumab and mFOLFOX6 in k - ras wild - type patients with senile colorectal cancer are effective and the adverse effect is able to be tolerated.